Download Champions' latest AACR 2025 Poster
An integrated preclinical platform for Antibody-Drug Conjugate development
Antibody-drug conjugates (ADCs) are a powerful class of cancer therapeutics that require precise target selection and robust validation. Champions Oncology has developed an integrated preclinical platform that combines molecular profiling, functional assays, and clinically relevant patient-derived xenograft (PDX) models to streamline ADC development and improve translational relevance.
- Developed by Champions Oncology, the integrated ADC development platform leverages over 1,500 PDX models, the proprietary Lumin multi-omics profiling system, and ex vivo/in vivo assays to identify novel ADC targets. Target validation includes expression analysis in tumors and normal tissues, ensuring tumor-specific targeting to reduce off-target effects.
- Target discovery and functional characterization involve high-throughput proteomics, isogenic cell lines, and internalization assays. Champions’ TumorGraft3D and NK cell adoptive transfer models allow for cytotoxicity evaluation and antibody-dependent cellular cytotoxicity (ADCC) testing, preserving human tumor complexity.
- One lead target (Target-1) was identified with limited expression in normal tissue and flow overlap with existing ADC targets. Despite similar expression in two colorectal PDX models, response to the candidate ADC varied, highlighting the need for patient-specific sensitivity profiling and the platform’s strength in refining ADC therapeutic strategies.
Download the Poster